Konrad Glund - Vivoryon Therapeutics CoFounder Advisor
| VVY Stock | 2.11 0.13 0.49% |
Insider
Konrad Glund is CoFounder Advisor of Vivoryon Therapeutics NV
| Age | 70 |
| Phone | 49 345 555 9900 |
| Web | https://www.vivoryon.com |
Vivoryon Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3283) % which means that it has lost $0.3283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6666) %, meaning that it generated substantial loss on money invested by shareholders. Vivoryon Therapeutics' management efficiency ratios could be used to measure how well Vivoryon Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | INSIDER Age | ||
| Anurag Relan | Pharming Group NV | 51 | |
| Jeroen Wakkerman | Pharming Group NV | 54 | |
| Susanne Embleton | Pharming Group NV | N/A | |
| MBA MD | Pharming Group NV | 63 | |
| Stephen Toor | Pharming Group NV | 52 | |
| Bruno Giannetti | Pharming Group NV | 71 | |
| Ruud Outersterp | Pharming Group NV | 59 | |
| Mireille MSc | Pharming Group NV | 55 | |
Management Performance
| Return On Equity | -0.67 | |||
| Return On Asset | -0.33 |
Vivoryon Therapeutics Leadership Team
Elected by the shareholders, the Vivoryon Therapeutics' board of directors comprises two types of representatives: Vivoryon Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vivoryon. The board's role is to monitor Vivoryon Therapeutics' management team and ensure that shareholders' interests are well served. Vivoryon Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vivoryon Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Florian Schmid, CFO Board | ||
| Manuela Bader, Director Communications | ||
| Konrad Glund, CoFounder Advisor | ||
| Michael Schaeffer, Chief Board | ||
| Ulrich Dauer, Chairman CEO | ||
| Frank MD, Chief Officer | ||
| Hendrik Liebers, Advisor |
Vivoryon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vivoryon Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | |||
| Return On Asset | -0.33 | |||
| Profit Margin | (1.26) % | |||
| Operating Margin | (1.34) % | |||
| Current Valuation | 240.95 M | |||
| Shares Outstanding | 24.11 M | |||
| Shares Owned By Insiders | 33.49 % | |||
| Shares Owned By Institutions | 25.10 % | |||
| Price To Book | 10.51 X | |||
| Price To Sales | 24.14 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivoryon Stock Analysis
When running Vivoryon Therapeutics' price analysis, check to measure Vivoryon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivoryon Therapeutics is operating at the current time. Most of Vivoryon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivoryon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivoryon Therapeutics' price. Additionally, you may evaluate how the addition of Vivoryon Therapeutics to your portfolios can decrease your overall portfolio volatility.